Study on Effects of GLP-1 Receptor Agonists on Dry Eye Disease in Adults with Type 2 Diabetes and Obesity

What this Trial Is About

This research aims to evaluate the effects of glucagon-like peptide-1 receptor agonists GLP-1 RAs on dry eye disease in patients with type 2 diabetes mellitus and obesity. Diabetes and obesity are increasing global health concerns, and these conditions are linked to eye problems like dry eye disease, which is often underdiagnosed. The study seeks to understand how newer antidiabetic medications may influence ocular surface health by assessing tear film stability and corneal changes. The study will include two groups 50 patients receiving GLP-1 receptor agonist therapy Semaglutide for overweight or obesity, with or without type 2 diabetes, and 50 control individuals matched by age, sex, and body mass index who will not receive this therapy. Participants will be observed over a period of 6 months to evaluate changes in ocular surface parameters. Participants will undergo ophthalmological assessments at two time points before starting GLP-1 RA therapy and after 6 months. These evaluations include measuring tear film break-up time, tear meniscus height, and corneal topography. Researchers will monitor changes in these ocular parameters to better understand the impact of GLP-1 RAs on dry eye disease. The study is observational and will last at least 6 months per participant.

Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity